Boehringer’s Striverdi Respimat Approved For COPD, But Without Exercise Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
The long-acting beta agonist olodaterol cleared FDA for treatment of chronic obstructive pulmonary disease, but it didn’t gain the differentiating claim the German pharma was seeking.